Astellas: Pfizer Buying Medivation Is the Best Possible Outcome for the Japan Pharma Firm
Pfizer is to pay US$81.50/shr for Medivation, considerably above Sanofi’s original offer of US$52.5bil. This values the Xtandi-originator at...
192 Views
Our Ultimate Stock-Pickers Top 10 New-Money Purchases
Our early read on the buying and selling activity of our top managers during the second quarter uncovered a few nuggets. New-money purchases were...
158 Views
A 'heads Up' on Changing World Heights
A comprehensive world survey of population heights over the last century has thrown up some surprising results. Americans have had the smallest...
165 Views
IRS Races to Complete Inversion Rules
Despite a backlog of public comments, the Internal Revenue Service is racing to finalize its proposed rules on earnings stripping by mid-October,...
171 Views
No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron
The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations...
169 Views